L- Arginine and Nitric Oxide Levels Among Children with Sickle Cell Disease Presented With Vaso-Occlusive Crisis in Federal Teaching Hospital Gombe, North Eastern Nigeria.
DOI:
https://doi.org/10.14738/bjhmr.101.13985Keywords:
L-arginine, nitric oxide, sickle cell disease, Vaso-occlusion crisisAbstract
Aim: The Aim of This Study Is To Evaluate The Level Of L- Arginine And Nitric Oxide Levels Among Children With Sickle Cell Disease presented with vaso-occlusive crisis in pediatric department, Federal Teaching Hospital Gombe, North Eastern Nigeria.
Methology: The area selected for this study was Federal Teaching Hospital (FTH), Gombe, Nigeria. Gombe State is located in the North- estern part of Nigeria. This study included 60 children aged 1-14 years with a confirmed HbSS electrophoretic pattern presented to the sickle cell clinic unit of Federal Teaching Hospital Gombe, Gombe State. About 5 millilitres of blood sample was collected from each subject aseptically using the venepuncture technique. The blood was collected into tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA) anticoagulant and the remaining samples was left undisturbed at room temperature and later centrifuged at 3000rpm for 5minutes to obtain clear non- haemolysed plasma. The plasma was transferred into sterile labelled test tubes and assayed (in batches) for l-arginine and Nitric Oxide.
Results: This study included children with a confirmed HbSS electrophoretic pattern aged 1-14 years with mean age 7.4500 ±0.50613 years, Presented to the sickle cell clinic unit of Federal Teaching Hospital Gombe, Gombe State. There was a statistically significant difference between the baseline and post L-arginine supplementation. The L-arginine and nitric oxide were significantly higher post supplementation compared to baseline levels among sickle cell disease subjects with vaso-occlusive crisis (p= 0.001and 0.01 respectively).
References
Adeyojin, A.S., Adedokum. and Idubor, N.T. (2015). “Knowledge, attitude and Control Practices of Sickle Cell Disease among Youth Corps Members in Benin City, Nigeria; Annals of Ibadan postgraduate medicin; 13(2): 100–107.
Kaul, D.K., Liu, X.D., Fabry, M.E. and Nagel, R.L. (2000). Impaired nitric oxide-mediated vasodilation in transgenic sickle mouse. American Journal Physiology Heart Circulation Physiology; 278(6): 1799–806.
Moncada, S. and Higgs, A. (1993). The L-arginine-nitric oxide pathway. New England Journal of Medical; 329 (27):2002–2012.
Morris, C.R., Kuypers, K.A., Larkin, S., Sweeters, N., Simon, J. Vichinsky, E.P., Styles, L.A. (2000). Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. British. Journal of Haematology; 111 498–500.
Morris, C. R., Kuypers, F., Alavrisha, L., Ansari, M., Sweeters, N., Stewart, M., Gildengorin, G., Neumayr, L. and Vichinsky, E. P. (2013). A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica; 98 (9): 1375.
Morris, C.R. (2014). Alterations of the arginine metabolome in sickle cell disease: a growing rationale for arginine therapy. Haematolology and Oncology Clinics of North America; 28(2): 301–321. 199
NPC/FRN (2007). Nigeria population commission Federal Republic of Nigeria. Special FGN Gazette no. 23 on the 2006 population census
Orki, H. and Higgs, D. R. (2010). “Sickle cell disease at 100 years. Science; 329 (5989) 291–292.
Reiter, C., Wang, X., Tanus-Santos, J., Hogg, N., Cannon, R. and Schechter, A. (2002). Cell-free hemoglobin limits nitric oxide bioavailability in sickle cell disease. Nature Medicine; 8(12):1383–1389.
Stuart, M. J. and. Nagel, R. L. (2004).“Sickle-cell disease,” The Lancet; 364 (9442):1343 –1360.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Abubakar, S., Erhabor, O., Ibrahim, K. K., Waziri, G., Ibrahim, A. B., Saleh Yuguda, Girei, A., Adamu, S., Isyaku, S., Tilako B. H.
This work is licensed under a Creative Commons Attribution 4.0 International License.
